Location History:
- Takaoka, JP (2017)
- Toyama, JP (2018)
Company Filing History:
2 out of 38 
2 out of 5 
2 out of 222 
Years Active: 2017-2018
Title: Shigeki Chiba – Pioneering Innovations in Anticancer Agents
Introduction
Shigeki Chiba, an esteemed inventor based in Toyama, Japan, is notable for his contributions to the field of cancer treatment through innovative pharmacological solutions. With a total of two patents under his name, Chiba has focused his research on the development of novel anticancer agents that address both tumor growth and the side effects associated with cancer therapies.
Latest Patents
Chiba's latest patents are focused on the creation of effective anticancer agents. One of his most significant inventions is an anticancer agent that combines arctigenin with other components to enhance antitumor effects while alleviating side effects. This invention proposes a combination drug or a kit containing a formulation with arctigenin and a formulation with another anticancer component, aimed at strongly inhibiting tumor growth and reducing cancer stem cells. His other notable invention involves an anticancer agent utilizing burdock fruit extract, which has shown tumor-reducing effects in pancreas cancer patients when a daily dose of arctigenin exceeds 100 mg. Additionally, the invention emphasizes the importance of the weight ratio of arctigenin to arctiin, establishing an effective range for optimal therapeutic outcomes.
Career Highlights
Chiba has a commendable track record in his professional career, having worked at renowned institutions such as the University of Toyama and Kracie Pharma, Ltd. His role in these organizations has allowed him to engage in significant research projects, particularly in the field of oncology.
Collaborations
Throughout his career, Shigeki Chiba has collaborated with influential peers, including Hiroyasu Esumi and Masafumi Ikeda. These collaborations have further enriched his research endeavors, contributing to the advancement of effective treatment options for cancer patients.
Conclusion
Shigeki Chiba's inventive spirit and dedication to the field of medicine are exemplified through his innovative anticancer agents. By merging cutting-edge research with practical applications, Chiba has made significant strides in improving patient outcomes, while also alleviating the side effects associated with conventional cancer therapies. His efforts serve as an inspiration to future inventors aspiring to make impactful changes in the medical landscape.